IBA Business Update Q1 2025
Year starting on track
Louvain-la-Neuve, Belgium, May 22 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter of 2025.
Group Overview
- Solid commercial momentum, particularly in IBA Clinical
- Equipment and Services backlog at €1.5 billion, with conversion executed in line with plan
- €9 million1 positive net cash position, decreasing vs. year-end. Foreseen backlog delivery activities impacting inventory and contract in progress build-up. New ventures (IBA Investments) and share buyback progress further contributing to this evolution
- Share buyback program ongoing since 25 March 2025, with 582,849 IBA ordinary shares purchased as of 19 May versus the announced target of 650,000 by the end of the year
- Appointment of Catherine Vandenborre as CFO and Head of the IBA Corporate Entity, starting 1 July 2025
Olivier Legrain, Chief Executive Officer of IBA commented: “We are pleased to report a solid start of the year, driven by good market momentum in Proton Therapy and positive trends in Dosimetry. IBA continues to execute its strategy towards sustained profitability, as outlined at the recent Capital Markets Day. The encouraging performance observed in the first quarter of 2025 reiterates our confidence in meeting our one-year guidance.”